CSIMarket Company Name, Ticker, Industry, else..
 
An2 Therapeutics Inc   (NASDAQ: ANTX)
 
Price: $5.2900 $-0.17 -3.114%
Day's High: $5.5 Week Perf: -7.68 %
Day's Low: $ 5.23 30 Day Perf: -11.69 %
Volume (M): 26,458 52 Wk High: $ 7.19
Volume (M$): $ 0 52 Wk Avg: $3.05
Open: $5.43 52 Wk Low: $1.00



 Market Capitalization (Millions $) 237
 Shares Outstanding (Millions) 45
 Employees 21
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) 35
 Capital Exp. (TTM) (Millions $) 0

Business Description


An2 Therapeutics Inc is a biotechnology company that focuses on developing novel therapies for neurological disorders. They aim to address unmet medical needs in the field of neurology through their innovative drug development programs. The company is dedicated to harnessing the potential of neuroscience research to create effective and safe treatments for patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Their mission is to improve the lives of individuals affected by neurological disorders by delivering transformative therapies.


   Company Address: 1300 El Camino Real Menlo Park 94025 CA
   Company Phone Number: 331-9090   Stock Exchange / Ticker: NASDAQ ANTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.08%    
JNJ   -2.91%    
LLY        2.13% 
MRK   -4.01%    
PFE   -1.57%    
TEVA        5.01% 
• View Complete Report
   



Business Update

AN2 Therapeutics Partners with GSK to Combat Tuberculosis with Innovative Boron-Based Therapies

Published Mon, Nov 10 2025 2:41 PM UTC

In a significant advancement in the fight against tuberculosis (TB), AN2 Therapeutics, Inc., a pioneering biopharmaceutical company based in Menlo Park, California, has announced a research collaboration with the global biopharmaceutical giant GlaxoSmithKline (GSK). This partnership aims to develop novel therapies utilizing boron-based leucyl-tRNA synthetase (LeuRS) inhibito...
Business Update

Combating Neglect The Promise of AN2 Therapeutics and DNDi in Chagas Disease and MAC Lung Disease Treatments,

Published Wed, Jul 23 2025 1:13 PM UTC

Chagas disease, caused by the parasite Trypanosoma cruzi , represents a significant public health challenge affecting approximately 6 to 7 million people worldwide. This neglected tropical disease can lead to severe chronic complications, including cardiomyopathy and gastrointestinal manifestations, severely impacting patients quality of life. Recent developments in medic...
Business Update

Pioneering the Future of Acute Melioidosis Treatment Insights from AN2 Therapeutics’ 200-Patient Observational Stud...

Published Mon, Jun 30 2025 12:47 PM UTC

Melioidosis, caused by the bacterium Burkholderia pseudomallei, presents a significant public health challenge, particularly in Southeast Asia and northern Australia. Characterized by a broad clinical spectrum, ranging from asymptomatic infections to severe, life-threatening conditions, melioidosis is notorious for its high mortality rates, which can reach up to 40% in sever...
Business Update

AN2 Therapeutics Implements Stockholder Rights Plan Amid Significant Share Accumulation Implications for Stakeholders

Published Fri, Aug 16 2024 1:10 PM UTC

AN2 Therapeutics, a biopharmaceutical firm dedicated to developing innovative small molecule therapeutics through its proprietary boron chemistry platform, has adopted a limited duration stockholder rights plan in response to a notable increase in ownership stakes by an investment partner. This article examines the motivations behind this strategic decision, its potential i...
Business Update

AN2 Therapeutics Epetraborole Shows Efficacy in Phase 2 Study for MAC Lung Disease, Paving the Way for Fut...

Published Fri, Aug 9 2024 5:10 AM UTC

AN2 Therapeutics Announces Promising Results for Epetraborole in Treating MAC Lung Disease Menlo Park, Calif. AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company renowned for its pioneering efforts in the development of small molecule therapeutics derived from its advanced boron chemistry platform, has made significant strides in the battle against treatme...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.12
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.04
Working Capital Ratio 14.32
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.07 $
Revenues (TTM) -
Cash Flow (TTM) 0.79 $
Cash 1.75 $
Book Value 1.7 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,727,429
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.